Lumos Diagnostics Holdings Limited (ASX: LDX) - Share Price
Current share price for LDX : $0.100 0.005 (4.76%)+
Lumos Diagnostics Holdings Limited (LDX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It , specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions.
LDX General Information +
| ASX Code | LDX |
| Website | N/A |
| Industry/Sector | Health Care Supplies |
| Market Cap ($M) | 97 |
| LDX Share Price | $0.100 |
| Day High | $0.105 |
| Day Low | $0.100 |
| Last Close | $0.105 |
| LDX Share Price Movement | $0.00 ( 4.76% ) |
Prices as at 16:40, 30 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Lumos Diagnostics Holdings Limited (LDX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Lumos Diagnostics Holdings Limited (LDX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Lumos Diagnostics Holdings Limited (LDX) price-sensitive announcements
LDX - FY26 Full Year Results Announcement
In FY26, Lumos Diagnostics Holdings Limited reported a revenue increase of 6% to US$13.2 m
Lumos Diagnostics Holdings Limited (LDX)
26 Aug 2026 | 9:44 AM
26 Aug 2026 | 9:44 AM
LDX - FY26 Appendix 4E
Lumos Diagnostics Holdings Limited released its Appendix 4E preliminary final report for t
Lumos Diagnostics Holdings Limited (LDX)
26 Aug 2026 | 9:22 AM
26 Aug 2026 | 9:22 AM
LDX - Lumos Receives FebriDx Order from PHASE Scientific
Lumos Diagnostics Holdings Limited announced receiving a US$767,800 purchase order from PH
Lumos Diagnostics Holdings Limited (LDX)
4 Aug 2026 | 9:04 AM
4 Aug 2026 | 9:04 AM
LDX - Quarterly Activities/Appendix 4C Cash Flow Report
Lumos Diagnostics released its Quarterly Activity Statement and Appendix 4C Cash Flow Repo
Lumos Diagnostics Holdings Limited (LDX)
27 Jul 2026 | 9:55 AM
27 Jul 2026 | 9:55 AM
Lumos Diagnostics Holdings Limited (LDX) Recent ASX Announcements
LDX Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$16.41 | -$2.00 | 25.50% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$10.97 | -$1.60 | -38.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$12.97 | -$2.60 | -51.40% | 0.00 | 0.00 | 0.00% | 0.0% |
LDX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Ansell Limited (ANN) | $6,202M | 0.1231 | -0.0919 | 0.1002 | 20.5696 | 22.6504 | 20.5869 | 2.24% | 1.86% | 2.06% |
| Lumos Diagnostics Holdings Limited (LDX) | $102M | 0.2547 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Nanosonics Limited (NAN) | $874M | -0.1375 | -0.3501 | 0.6933 | 50.6066 | 77.8667 | 45.9843 | 0.00% | 0.00% | 0.00% |
| Polynovo Limited (PNV) | $642M | -0.0899 | -0.4186 | 1.0000 | 54.0698 | 93.0000 | 46.5000 | 0.00% | 0.00% | 0.00% |
LDX Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Doug Ward | Chief Executive Officer, Managing Director | 13 Jul 2023 |
| Mr Samuel Ross Garland Lanyon | Non-Executive Chairman, Non-Executive Director | 7 Dec 2018 |
| Mr Lawrence Mehren | Non-Executive Deputy Chairman, Non-Executive Director | 16 Dec 2020 |
| Ms Bronwyn Joyce Le Grice | Non-Executive Director | 1 Nov 2020 |
| Ms Catherine Robson | Non-Executive Director | 26 Dec 2020 |
Lumos Diagnostics Holdings Limited (LDX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Aug 2026 | WARD, Doug | Buy | Direct Shares | 202,131 | $0.105 | $21,223.760 |
| 23 Jun 2026 | LANYON, Samuel | Buy | Direct Shares | 249,725 | $0.120 | $29,967.000 |
| 16 Jun 2026 | ROBSON, Catherine | Buy | Indirect Shares | 300,000 | $0.105 | $31,399.990 |
See all changes in directors' interest & trades for Lumos Diagnostics Holdings Limited (LDX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
LDX Management
| Name | Position |
|---|---|
| Barrie Lambert | Chief Financial Officer |
| Sacha Dopheide | Chief Technology Officer |
| Tracy Weimar | Company Secretary |
| Paul Kase | Senior Vice President Commercial Operations |
| Sarah Glubka | Vice President of Human Resource |
| Annie Bell | Vice President of Medical Affairs |
| Anthony Favaloro | Vice President of Operations |
| Mike Raymundo | Vice President of Product Development |
| Sue Hibbeln | Vice President of Quality and Regulatory Affairs |
| Jon Gary | Vice President of Research and Development |
LDX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Lumos Diagnostics Holdings Limited (LDX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 148,672,643 (19.93%) | Tenmile Ventures Pty Ltd |
| 127,039,660 (17.03%) | Ryder Capital Limited |
LDX Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 02 March 2027 | Report (Interim) |
| 26 February 2027 | Report (Interim) |
| 13 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
